Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
October 11, 2023 09:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two...
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
October 09, 2023 08:15 ET
|
AnaptysBio, Inc.
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering...
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
October 09, 2023 08:00 ET
|
AnaptysBio, Inc.
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo...
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
September 18, 2023 16:15 ET
|
AnaptysBio, Inc.
After more than 15 years serving on AnaptysBio’s Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023...
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
September 12, 2023 09:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023 16:15 ET
|
AnaptysBio, Inc.
Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023Initiating a global Phase 2b trial for...
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
July 31, 2023 13:34 ET
|
AnaptysBio, Inc.
JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapyU.S. Food and Drug Administration approval represents a...
AnaptysBio Announces Participation in Upcoming Investor Conferences
May 30, 2023 16:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
May 11, 2023 16:15 ET
|
AnaptysBio, Inc.
Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for...
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
May 02, 2023 09:15 ET
|
AnaptysBio, Inc.
Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4Flare control sustained on monthly subcutaneous doses through Week 16Imsidolimab...